002370 亚太药业
已收盘 04-30 15:00:00
资讯
新帖
简况
亚太药业（002370）2025年一季报简析：净利润减160.25%
证券之星 · 04-30
亚太药业（002370）2025年一季报简析：净利润减160.25%
图解亚太药业一季报：第一季度单季净利润同比减160.25%
证券之星 · 04-29
图解亚太药业一季报：第一季度单季净利润同比减160.25%
亚太药业(002370.SZ)发布一季度业绩，归母净亏损780.32万元，扩大160.25%
智通财经 · 04-29
亚太药业(002370.SZ)发布一季度业绩，归母净亏损780.32万元，扩大160.25%
亚太药业：公司2024年年度报告已于2025年4月25日披露
证券之星 · 04-29
亚太药业：公司2024年年度报告已于2025年4月25日披露
亚太药业：注射用阿昔洛韦通过仿制药一致性评价 将进一步丰富公司产品管线
中国财富通 · 04-28
亚太药业：注射用阿昔洛韦通过仿制药一致性评价 将进一步丰富公司产品管线
图解亚太药业年报：第四季度单季净利润同比增386.96%
证券之星 · 04-24
图解亚太药业年报：第四季度单季净利润同比增386.96%
亚太药业：收到政府补助300万元
美港电讯 · 04-18
亚太药业：收到政府补助300万元
亚太药业：公司目前未与DeepSeek开展业务合作
证券之星 · 04-15
亚太药业：公司目前未与DeepSeek开展业务合作
【亚太药业：选举宋凌杰为董事长】 亚太药业4月15日公告，董事会会议同意选举宋凌杰为公司第八届董事会董事长，选举黄小明为公司第八届董事会副董事长；同意聘任岑建维为公司总经理，聘任谭钦水为公司副总经理。
金融界 · 04-15
【亚太药业：选举宋凌杰为董事长】 亚太药业4月15日公告，董事会会议同意选举宋凌杰为公司第八届董事会董事长，选举黄小明为公司第八届董事会副董事长；同意聘任岑建维为公司总经理，聘任谭钦水为公司副总经理。
亚太药业：选举宋凌杰为董事长
美港电讯 · 04-15
亚太药业：选举宋凌杰为董事长
亚太药业：公司目前暂未利用AI
证券之星 · 03-10
亚太药业：公司目前暂未利用AI
亚太药业（002370）2月19日主力资金净卖出444.15万元
证券之星 · 02-20
亚太药业（002370）2月19日主力资金净卖出444.15万元
亚太药业最新公告：公司注射用替加环素获得药品注册证书
证券之星 · 02-07
亚太药业最新公告：公司注射用替加环素获得药品注册证书
亚太药业(002370.SZ)：注射用替加环素获得药品注册证书
智通财经 · 02-07
亚太药业(002370.SZ)：注射用替加环素获得药品注册证书
亚太药业最新公告：注射用盐酸地尔硫䓬通过一致性评价
证券之星 · 02-06
亚太药业最新公告：注射用盐酸地尔硫䓬通过一致性评价
【亚太药业：注射用盐酸地尔硫䓬通过一致性评价】 亚太药业2月6日晚间公告，公司近日收到国家药监局核准签发的关于注射用盐酸地尔硫䓬的《药品补充申请批准通知书》，公司注射用盐酸地尔硫䓬通过仿制药质量和疗效一致性评价。
金融界 · 02-06
【亚太药业：注射用盐酸地尔硫䓬通过一致性评价】 亚太药业2月6日晚间公告，公司近日收到国家药监局核准签发的关于注射用盐酸地尔硫䓬的《药品补充申请批准通知书》，公司注射用盐酸地尔硫䓬通过仿制药质量和疗效一致性评价。
亚太药业（002370）1月17日主力资金净买入7779.41万元
证券之星 · 01-20
亚太药业（002370）1月17日主力资金净买入7779.41万元
1月17日亚太药业涨停分析：幽门螺杆菌概念，化学原料药，创新药概念热股
证券之星 · 01-17
1月17日亚太药业涨停分析：幽门螺杆菌概念，化学原料药，创新药概念热股
异动快报：亚太药业（002370）1月17日11点2分触及涨停板
证券之星 · 01-17
异动快报：亚太药业（002370）1月17日11点2分触及涨停板
加载更多
公司概况
公司名称：
浙江亚太药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-03-16
主营业务：
浙江亚太药业股份有限公司主要从事医药制造业务，包括化学制剂、化学原料药的研发、生产和销售。公司主要产品包括抗阿莫西林克拉维酸钾分散片、阿奇霉素分散片、注射用阿奇霉素、罗红霉素胶囊、注射用头孢唑肟钠等。罗红霉素胶囊、头孢氨苄胶囊、阿奇霉素分散片及注射用阿奇霉素为本公司的主导产品。
发行价格：
16.00
{"stockData":{"symbol":"002370","market":"SZ","secType":"STK","nameCN":"亚太药业","latestPrice":3.13,"timestamp":1745996589000,"preClose":3.24,"halted":0,"volume":36793166,"delay":0,"changeRate":-0.034,"floatShares":746000000,"shares":746000000,"eps":0.0395,"marketStatus":"已收盘","change":-0.11,"latestTime":"04-30 15:00:00","open":3.21,"high":3.24,"low":3.12,"amount":116000000,"amplitude":0.037,"askPrice":3.14,"askSize":6002,"bidPrice":3.13,"bidSize":1665,"shortable":0,"etf":0,"ttmEps":0.0395,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"adjPreClose":3.24,"symbolType":"stock","openAndCloseTimeList":[[1745976600000,1745983800000],[1745989200000,1745996400000]],"highLimit":3.56,"lowLimit":2.92,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":745667530,"isCdr":false,"pbRate":2.66,"roa":"--","peRate":79.240506,"roe":"--","epsLYR":0.05,"committee":0.189801,"marketValue":2334000000,"turnoverRate":0.0493,"status":1,"floatMarketCap":2334000000},"requestUrl":"/m/hq/s/002370","defaultTab":"news","newsList":[{"id":"2532401800","title":"亚太药业（002370）2025年一季报简析：净利润减160.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532401800","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532401800?lang=zh_cn&edition=full","pubTime":"2025-05-01 06:53","pubTimestamp":1746053593,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期亚太药业发布2025年一季报。根据财报显示，亚太药业净利润减160.25%。截至本报告期末，公司营业总收入6455.05万元，同比下降42.73%，归母净利润-780.32万元，同比下降160.25%。去年的净利率为8.45%，算上全部成本后，公司产品或服务的附加值一般。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050100005433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2531786467","title":"图解亚太药业一季报：第一季度单季净利润同比减160.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531786467","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531786467?lang=zh_cn&edition=full","pubTime":"2025-04-29 19:02","pubTimestamp":1745924559,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业2025年一季报显示，公司主营收入6455.05万元，同比下降42.73%；归母净利润-780.32万元，同比下降160.25%；扣非净利润-756.38万元，同比下降242.05%；负债率30.75%，财务费用-59.91万元，毛利率31.35%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900036983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2531206566","title":"亚太药业(002370.SZ)发布一季度业绩，归母净亏损780.32万元，扩大160.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531206566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531206566?lang=zh_cn&edition=full","pubTime":"2025-04-29 17:25","pubTimestamp":1745918722,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)发布2025年第一季度报告，该公司营业收入为6455.05万元，同比减少42.73%。归属于上市公司股东的净亏损为780.32万元，同比扩大160.25%。归属于上市公司股东的扣除非经常性损益的净亏损为756.38万元，同比扩大242.05%。基本每股亏损为0.0105元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1287413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0132","002370"],"gpt_icon":0},{"id":"2531278128","title":"亚太药业：公司2024年年度报告已于2025年4月25日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2531278128","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531278128?lang=zh_cn&edition=full","pubTime":"2025-04-29 15:54","pubTimestamp":1745913249,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业(002370)04月29日在投资者关系平台上答复投资者关心的问题。投资者提问：年报什么时候发，请精确到小时亚太药业回复：您好，感谢您对公司的关注！公司2024年年度报告已于2025年4月25日披露。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042900026290.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2530427549","title":"亚太药业：注射用阿昔洛韦通过仿制药一致性评价 将进一步丰富公司产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2530427549","media":"中国财富通","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530427549?lang=zh_cn&edition=full","pubTime":"2025-04-28 17:31","pubTimestamp":1745832711,"startTime":"0","endTime":"0","summary":"4月28日，亚太药业（002370）公告称，公司于近日收到国家药品监督管理局核准签发的关于注射用阿昔洛韦的《药品补充申请批准通知书》，公司注射用阿昔洛韦通过仿制药质量和疗效一致性评价。公司本次注射用阿昔洛韦通过仿制药质量和疗效一致性评价，将进一步丰富公司的产品管线，有利于提升该药品的市场竞争力，同时为公司后续其他产品开展仿制药一致性评价工作积累经验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=G%2FLQurIQqIY%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2530683469","title":"图解亚太药业年报：第四季度单季净利润同比增386.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530683469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530683469?lang=zh_cn&edition=full","pubTime":"2025-04-25 00:58","pubTimestamp":1745513927,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业2024年年报显示，公司主营收入4.05亿元，同比下降3.68%；归母净利润3423.98万元，同比上升388.29%；扣非净利润-2813.19万元，同比上升59.2%；其中2024年第四季度，公司单季度主营收入9833.89万元，同比下降17.21%；单季度归母净利润3769.93万元，同比上升386.96%；单季度扣非净利润-553.99万元，同比上升48.57%；负债率30.65%，投资收益5381.68万元，财务费用1964.64万元，毛利率31.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2528304031","title":"亚太药业：收到政府补助300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2528304031","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2528304031?lang=zh_cn&edition=full","pubTime":"2025-04-18 15:55","pubTimestamp":1744962917,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2527410977","title":"亚太药业：公司目前未与DeepSeek开展业务合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2527410977","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527410977?lang=zh_cn&edition=full","pubTime":"2025-04-15 20:51","pubTimestamp":1744721495,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业(002370)04月14日在投资者关系平台上答复投资者关心的问题。投资者提问：人工智能这么火、特别是DEEPSEEK，公司有应用吗？亚太药业回复：您好，感谢您对公司的关注！公司目前未与DeepSeek开展业务合作，公司始终密切关注人工智能等前沿技术的发展趋势，谢谢。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025041500034959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370"],"gpt_icon":0},{"id":"2527491507","title":"【亚太药业：选举宋凌杰为董事长】 亚太药业4月15日公告，董事会会议同意选举宋凌杰为公司第八届董事会董事长，选举黄小明为公司第八届董事会副董事长；同意聘任岑建维为公司总经理，聘任谭钦水为公司副总经理。","url":"https://stock-news.laohu8.com/highlight/detail?id=2527491507","media":"金融界","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527491507?lang=zh_cn&edition=full","pubTime":"2025-04-15 19:14","pubTimestamp":1744715646,"startTime":"0","endTime":"0","summary":"亚太药业4月15日公告，董事会会议同意选举宋凌杰为公司第八届董事会董事长，选举黄小明为公司第八届董事会副董事长；同意聘任岑建维为公司总经理，聘任谭钦水为公司副总经理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/04/15191449556807.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2527491339","title":"亚太药业：选举宋凌杰为董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2527491339","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527491339?lang=zh_cn&edition=full","pubTime":"2025-04-15 19:12","pubTimestamp":1744715531,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2518229347","title":"亚太药业：公司目前暂未利用AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2518229347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518229347?lang=zh_cn&edition=full","pubTime":"2025-03-10 20:52","pubTimestamp":1741611124,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业(002370)03月10日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，贵公司有利用ai吗亚太药业回复：您好，感谢您对公司的关注！公司目前暂未利用AI。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025031000031752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2512832450","title":"亚太药业（002370）2月19日主力资金净卖出444.15万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512832450","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512832450?lang=zh_cn&edition=full","pubTime":"2025-02-20 09:26","pubTimestamp":1740014801,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年2月19日收盘，亚太药业报收于3.36元，上涨0.0%，换手率2.84%，成交量20.71万手，成交额6937.54万元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入411.49万元，融资偿还491.04万元，融资净偿还79.55万元。亚太药业主营业务：医药制造业务,包括化学制剂的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022000008086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0},{"id":"2509979253","title":"亚太药业最新公告：公司注射用替加环素获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2509979253","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509979253?lang=zh_cn&edition=full","pubTime":"2025-02-07 17:03","pubTimestamp":1738919031,"startTime":"0","endTime":"0","summary":"亚太药业公告称，公司近日收到国家药品监督管理局核准签发的关于注射用替加环素的《药品注册证书》。该药品适用于18岁及以上患者由特定细菌的敏感菌株所致的感染，包括复杂性腹腔内感染、复杂性皮肤和皮肤软组织感染、社区获得性细菌性肺炎等。根据国家相关政策规定，本次获得注射用替加环素《药品注册证书》视同通过仿制药质量和疗效一致性评价，有利于丰富公司产品线，提升市场竞争力。然而，由于药品销售受到国家政策、市场环境等因素影响，存在不确定性，投资者需谨慎决策，注意投资风险。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020700026385.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2509799076","title":"亚太药业(002370.SZ)：注射用替加环素获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2509799076","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509799076?lang=zh_cn&edition=full","pubTime":"2025-02-07 16:33","pubTimestamp":1738917206,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚太药业(002370.SZ)发布公告，公司于近日收到国家药品监督管理局核准签发的关于注射用替加环素的《药品注册证书》。根据国家相关政策规定，本次获得注射用替加环素《药品注册证书》视同通过仿制药质量和疗效一致性评价，有利于丰富公司产品线，提升公司产品市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1247089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚太药业(002370.SZ)：注射用替加环素获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002370","BK0239","BK0132"],"gpt_icon":0},{"id":"2509223796","title":"亚太药业最新公告：注射用盐酸地尔硫䓬通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2509223796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509223796?lang=zh_cn&edition=full","pubTime":"2025-02-06 18:29","pubTimestamp":1738837788,"startTime":"0","endTime":"0","summary":"亚太药业公告，公司近日收到国家药监局核准签发的关于注射用盐酸地尔硫䓬的《药品补充申请批准通知书》，公司注射用盐酸地尔硫䓬通过仿制药质量和疗效一致性评价。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025020600031739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2509722391","title":"【亚太药业：注射用盐酸地尔硫䓬通过一致性评价】 亚太药业2月6日晚间公告，公司近日收到国家药监局核准签发的关于注射用盐酸地尔硫䓬的《药品补充申请批准通知书》，公司注射用盐酸地尔硫䓬通过仿制药质量和疗效一致性评价。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509722391","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509722391?lang=zh_cn&edition=full","pubTime":"2025-02-06 18:28","pubTimestamp":1738837685,"startTime":"0","endTime":"0","summary":"亚太药业2月6日晚间公告，公司近日收到国家药监局核准签发的关于注射用盐酸地尔硫䓬的《药品补充申请批准通知书》，公司注射用盐酸地尔硫䓬通过仿制药质量和疗效一致性评价。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/06182847990824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002370","BK0132","BK0239"],"gpt_icon":0},{"id":"2504741295","title":"亚太药业（002370）1月17日主力资金净买入7779.41万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504741295","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504741295?lang=zh_cn&edition=full","pubTime":"2025-01-20 09:11","pubTimestamp":1737335475,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月17日收盘，亚太药业报收于3.33元，上涨9.9%，涨停，换手率10.51%，成交量76.54万手，成交额2.48亿元。近5日资金流向一览见下表：亚太药业融资融券信息显示，融资方面，当日融资买入619.4万元，融资偿还773.67万元，融资净偿还154.28万元。亚太药业主营业务：医药制造业务,包括化学制剂的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012000002566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","002370","BK0239"],"gpt_icon":0},{"id":"2504818961","title":"1月17日亚太药业涨停分析：幽门螺杆菌概念，化学原料药，创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2504818961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504818961?lang=zh_cn&edition=full","pubTime":"2025-01-17 15:29","pubTimestamp":1737098945,"startTime":"0","endTime":"0","summary":"证券之星消息，亚太药业1月17日涨停收盘，收盘价3.33元。该股于11点2分涨停，未打开涨停，截止收盘封单资金为5033.36万元，占其流通市值2.07%。近5日资金流向一览见下表：该股为幽门螺杆菌概念，化学原料药，创新药概念热股，当日幽门螺杆菌概念概念上涨0.58%，化学原料药概念上涨0.34%，创新药概念上涨0.32%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011700019738.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","06978","159992","BK1161","002370","BK0132"],"gpt_icon":0},{"id":"2504908184","title":"异动快报：亚太药业（002370）1月17日11点2分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2504908184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504908184?lang=zh_cn&edition=full","pubTime":"2025-01-17 11:05","pubTimestamp":1737083119,"startTime":"0","endTime":"0","summary":"证券之星1月17日盘中消息，11点2分亚太药业（002370）触及涨停板。目前价格3.33，上涨9.9%。其所属行业化学制药目前下跌。领涨股为润都股份。该股为幽门螺杆菌概念，创新药，化学原料药概念热股。1月16日的资金流向数据方面，主力资金净流出584.1万元，占总成交额7.11%，游资资金净流入460.91万元，占总成交额5.61%，散户资金净流入123.18万元，占总成交额1.5%。近5日资金流向一览见下表：亚太药业主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025011700014032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002370","BK0132"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746492836982,"stockEarnings":[{"period":"1week","weight":-0.0457},{"period":"1month","weight":-0.0601},{"period":"3month","weight":-0.0457},{"period":"6month","weight":-0.0126},{"period":"1year","weight":-0.0457},{"period":"ytd","weight":0.0262}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.017},{"period":"3month","weight":0.0087},{"period":"6month","weight":0.0021},{"period":"1year","weight":0.0561},{"period":"ytd","weight":-0.0217}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江亚太药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"60792人(较上一季度减少11.90%)","perCapita":"12265股","listingDate":"2010-03-16","address":"浙江省绍兴市柯桥区群贤路2003号1501室","registeredCapital":"74566万元","survey":" 浙江亚太药业股份有限公司主要从事医药制造业务，包括化学制剂、化学原料药的研发、生产和销售。公司主要产品包括抗阿莫西林克拉维酸钾分散片、阿奇霉素分散片、注射用阿奇霉素、罗红霉素胶囊、注射用头孢唑肟钠等。罗红霉素胶囊、头孢氨苄胶囊、阿奇霉素分散片及注射用阿奇霉素为本公司的主导产品。","listedPrice":16},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚太药业,002370,亚太药业股票,亚太药业股票老虎,亚太药业股票老虎国际,亚太药业行情,亚太药业股票行情,亚太药业股价,亚太药业股市,亚太药业股票价格,亚太药业股票交易,亚太药业股票购买,亚太药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚太药业(002370)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚太药业(002370)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}